About this trial
In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density (SV2A PET), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep EEG) in both migraine and healthy control participants before and one week after the administration of psilocybin or an active control agent.
Eligibility criteria
Qualifiers
Age 21 to 70 (inclusive)
Migraine disease per ICHD-3 criteria (for migraine participants) OR Healthy control patient
Unstable medical condition or serious nervous system pathology
Pregnant, breastfeeding, lack of adequate birth control
Disqualifiers
None
Trial design
Treatments tested in this trial
- Psilocybin
- Placebo
Treatment groups
Sponsors and collaborators
Yale University
Lead sponsor
The Wallace Foundation
Collaborator